Empagliflozin moved sodium in refractory ascites, in twenty-one patients over ten days

Design

randomised, open-label, proof-of-concept study over 10 days

Population

21 adults with type 2 diabetes, decompensated cirrhosis and refractory ascites

Primary outcome

between-group difference in change in fractional excretion of sodium

Effect

+0.44 percentage points (95% CI 0.05-0.83); urinary sodium +92.1 mmol/24h; paracentesis 0.6 vs 1.3 L/day

Refractory ascites is defined by the failure of diuretics, and the nephrological problem underneath it is avid proximal sodium reabsorption that loop and distal agents cannot overcome. An SGLT2 inhibitor acts proximally, which is the mechanistic argument for trying one.

This open-label study randomised 21 adults with type 2 diabetes, decompensated cirrhosis and refractory ascites to empagliflozin 10 mg daily plus standard care or standard care alone for ten days. Fractional sodium excretion rose by 0.44 percentage points more with treatment (95% CI 0.05-0.83, p = 0.029). Twenty-four-hour urinary sodium rose by 92.1 mmol (47.1-137.2) and urine volume by 822 mL (403-1240). Mean daily paracentesis volume was 0.6 L/day against 1.3 L/day. No serious adverse events occurred.

Ten patients received the drug, for ten days, unblinded, with a biochemical primary endpoint. That is a hypothesis-generating study and the authors say so. Two cautions belong in any discussion of it: this population is exactly where volume depletion and hepatorenal physiology make aggressive natriuresis dangerous, and SGLT2 inhibitors carry euglycaemic ketoacidosis risk that rises in decompensated cirrhosis with poor intake. The mechanism is attractive and the signal is consistent across four measures, which is why it deserves a proper trial rather than adoption.

• Do not start an SGLT2 inhibitor for ascites outside a trial on this evidence.
• Ten patients received the drug for ten days, with a biochemical primary endpoint.
• The mechanism is proximal natriuresis, which is where diuretic resistance in cirrhosis sits.
• Watch for euglycaemic ketoacidosis in decompensated cirrhosis with poor oral intake.
• Monitor creatinine and sodium closely in anyone already on an SGLT2 inhibitor who decompensates.

Why it matters

Refractory ascites has almost no pharmacological options, and this targets the mechanism that makes it refractory.

Don't overread it

Open-label, 21 patients, ten days, biochemical endpoints - it does not establish clinical benefit or safety.

The statistics, in plain English

A between-group difference of 0.44 percentage points in fractional sodium excretion with a lower confidence limit of 0.05 is statistically positive by the narrowest margin, and in 21 patients that is fragile. The more persuasive feature is consistency: sodium excretion, urine volume and paracentesis requirement all moved in the same direction with intervals well clear of zero. Consistency across related measures is weaker than replication but stronger than a single endpoint.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.